These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9063906)

  • 21. Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis.
    Sa DS; Kapur S; Lang AE
    Clin Neuropharmacol; 2001; 24(4):242-4. PubMed ID: 11479398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.
    Rich SS; Friedman JH; Ott BR
    J Clin Psychiatry; 1995 Dec; 56(12):556-9. PubMed ID: 8530331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of pharmacotoxic psychoses with clopenthixol in patients with Parkinson's disease (author's transl)].
    Danielczyk W
    Wien Klin Wochenschr; 1981 Aug; 93(15):500-1. PubMed ID: 7303692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Value of clozapine in treatment of psychotic disorder in Parkinson disease].
    Abbar M; Courtet P; Castelnau D
    Encephale; 1996; 22(1):53-63. PubMed ID: 8681876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Three patients with Parkinson's disease whose therapeutic levels were successfully improved after administration of quetiapine for suppression of psychosis].
    Kodama R; Morita S; Miwa H; Kondo T
    No To Shinkei; 2003 May; 55(5):413-7. PubMed ID: 12833883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Exogenous psychoses in Parkinson syndrome. Frequency and causal conditions].
    Schneider E; Fischer PA; Jacobi P; Grotz A
    Fortschr Neurol Psychiatr; 1984 Jun; 52(6):207-14. PubMed ID: 6745832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comt inhibition in the treatment of Parkinson's disease: neuroprotection and future perspectives.
    Kostić VS
    Adv Exp Med Biol; 2004; 541():75-90. PubMed ID: 14977209
    [No Abstract]   [Full Text] [Related]  

  • 28. Reversal of antiparkinsonian drug toxicity by physostigmine: a controlled study.
    el-Yousef MK; Janowsky D; Davis JM; Sekerke HJ
    Am J Psychiatry; 1973 Feb; 130(2):141-5. PubMed ID: 4405503
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review.
    Widman LP; Burke WJ; Pfeiffer RF; McArthur-Campbell D
    J Geriatr Psychiatry Neurol; 1997 Apr; 10(2):63-6. PubMed ID: 9188021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Psychosis due to the interaction of erythromycin and bromocriptine in Parkinson disease].
    Alegre M; Noé E; Martínez Lage JM
    Neurologia; 1997 Nov; 12(9):429. PubMed ID: 9471184
    [No Abstract]   [Full Text] [Related]  

  • 31. Mental disorders in Parkinson's disease.
    Rafal R
    R I Med J (1976); 1986 Jul; 69(7):323-6. PubMed ID: 3462889
    [No Abstract]   [Full Text] [Related]  

  • 32. [Levodopa-induced psychosis in patients with idiopathic Parkinson disease].
    García-Escrig M; Bermejo Pareja F; Fernández Ponsatí JT
    Med Clin (Barc); 1999 Feb; 112(7):245-50. PubMed ID: 10220750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
    Arnold G; Trenkwalder C; Schwarz J; Oertel WH
    Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
    [No Abstract]   [Full Text] [Related]  

  • 34. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease.
    Barbato L; Monge A; Stocchi F; Nordera G
    Funct Neurol; 1996; 11(4):201-7. PubMed ID: 8934152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.
    Fernandez HH; Lannon MC; Friedman JH; Abbott BP
    Mov Disord; 2000 May; 15(3):579-81. PubMed ID: 10830427
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of mianserin on the severity of psychosis and dyskinesia in the parkinsonian marmoset.
    Hamadjida A; Nuara SG; Gourdon JC; Huot P
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():367-371. PubMed ID: 28882428
    [No Abstract]   [Full Text] [Related]  

  • 37. [Ziprasidone in Parkinsonian dopamine psychosis].
    Durán-Ferreras E; Alvarez-López M; García-Moreno JM; Chacón J
    Rev Neurol; 2008 Apr 16-30; 46(8):476-80. PubMed ID: 18428105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The treatment of Parkinson disease].
    Jiménez-Jiménez FJ
    Med Clin (Barc); 1999 Feb; 112(7):257-8. PubMed ID: 10220753
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.
    Papapetropoulos S
    Clin Neuropharmacol; 2006; 29(1):59. PubMed ID: 16518136
    [No Abstract]   [Full Text] [Related]  

  • 40. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease.
    Parkinson Study Group
    N Engl J Med; 1999 Mar; 340(10):757-63. PubMed ID: 10072410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.